TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

✍ Scribed by Lasho, T L; Tefferi, A; Hood, J D; Verstovsek, S; Gilliland, D G; Pardanani, A

• Book ID: 109886796
• Publisher: Nature Publishing Group
• Year: 2008
• Tongue: English
• Weight: 103 KB
• Volume: 22
• Category: Article
• ISSN: 0887-6924
• DOI: 10.1038/leu.2008.56